April 30, 2021: Janssen (Johnson & Johnson) COVID-19 Vaccine FAQs
Per an FDA and CDC joint statement, the IDPH, Cook County Health and Chicago Department of Health had recently paused and since resumed the distribution of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of six people experiencing rare blood clots within two weeks of receiving the one-dose vaccine. NorthShore would like to share some guidance with our community members regarding concerns about this vaccine.
Has NorthShore administered the Johnson & Johnson COVID-19 vaccine?
No. NorthShore is only using the Pfizer and Moderna vaccines and have not received any Johnson & Johnson vaccines. NorthShore will follow CDC guidance if we do receive it in the future.
How many people have received the Johnson & Johnson COVID vaccine and who have developed blood clots?
Over seven million doses have been administered in the United States. Six women age 50 and underdeveloped blood clots within two weeks of receiving the vaccine. One individual has died and another is critically ill.
Are these blood clots common?
No. The blood clot, called cerebral venous sinus thrombosis, is a very rare clotting disorder that affects the head and brain. Additionally, the impacted patients also experienced thrombocytopenia or low levels of blood platelets.
What are the symptoms patients should look out for within the first three weeks after receiving the Johnson & Johnson vaccine?
Presentation can vary greatly depending on the location and extent of the thrombosis (blood clotting). People may experience the following symptoms:
- Severe or persistent headache that comes on gradually but increases in intensity over days;
- Facial weakness, blurred vision, deafness, vomiting, seizures or confusion;
- Shortness of breath, chest pain, leg swelling or persistent abdominal pain;
- Unusual skin bruising or pinpoint bleeding spots in the skin beyond the injection site.
For the most up-to-date COVID-19 and vaccine information, visit NorthShore.org.